To develop and conduct clinical trials aimed at improving the treatment and prevention of cancer with the ultimate goal of reducing morbidity and mortality from this disease.
The NCIC Clinical Trials Group is a cooperative oncology group which carries out clinical trials in cancer therapy, supportive care and prevention across Canada and internationally. It is one of the national programmes and networks of the Canadian Cancer Society Research Institute (CCSRI), and is supported by the Canadian Cancer Society (CCS).
InformationThe information contained in this website is intended for use by NCIC Clinical Trials Group members at participating centres.
A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (> = to 65 years of age) with Chronic Lymphocytic Leukemia (CLL)
A Prospective Economic Analysis of NCIC CTG CLC.2/ALLIANCE A041202: A Randomized Phase III CLL Study of Bendamustine Plus Rituximab versus Ibrutinib Plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (>= 65 Years of Age) With Chronic Lymphocytic Leukemia
Phase II Study of Buparlisib in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia
A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Cisplatin Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer
A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Change In Mammographic Density with Metformin Use: MA32 Companion Study
Randomised Phase III Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
Corticosteroid with either Bevacizumab or Placebo for Radionecrosis after Surgery for Brain Metastases
Radiotherapy with Temozolomide versus Radiotherapy with PCV Chemotherapy for 1p/19q Co-deleted Anaplastic or Low Grade Glioma
Adjuvant Olaparib vs Placebo in Patients with BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer
Phase III Study of Palliative Radiotherapy for Hepatocellular Carcinoma and Liver Metastases
Adjuvant Peginterferon alfa-2b vs Observation in Patients with Ulcerated Primary Cutaneous Melanoma
Randomized Phase II Study Comparing the Met Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Sorafenib vs Placebo in Desmoid Tumors or Aggressive Fibromatosis
A Phase II Feasibility Study Comparing Stereotactic Body Radiotherapy (SBRT) versus Conventional Palliative Radiotherapy for Patients with Spinal Metastases